Related Experiment Video

Updated: Apr 17, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

13.7K

[Diagnostics and treatment of phenylketonuria]

Allan Bayat1, Libeth Birk Møller, Allan Meldgaard Lund

  • 1Klinisk Genetisk Klinik, Rigshospitalet, Blegdamsvej 9, 2100 København. bayabayabayat@hotmail.com.

Ugeskrift for Laeger
|February 21, 2015
PubMed

Insights

Phenylketonuria, a phenylalanine hydroxylase deficiency, causes high blood phenylalanine. Early treatment is key, though some patients may face psychological and neurodevelopmental issues. This review covers PKU management and new treatments.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Phenylketonuria (PKU) is an inherited metabolic disorder caused by primary phenylalanine hydroxylase deficiency.
  • This deficiency leads to the accumulation of phenylalanine in the blood, potentially causing severe health issues if untreated.

Purpose of the Study:

  • To provide a comprehensive review of phenylketonuria.
  • To discuss the symptoms, diagnosis, classification, and management strategies for PKU.
  • To explore emerging pharmacological and non-pharmacological treatment options.

Main Methods:

  • Literature review of existing studies on phenylketonuria.
  • Synthesis of information on PKU symptoms, diagnosis, and classification.
  • Analysis of current and novel treatment and management approaches.

Main Results:

  • Early identification and intervention significantly prevent most clinical sequelae of PKU.
  • Despite treatment, some individuals may still experience psychological and neurodevelopmental challenges.
  • A range of treatment strategies, including dietary management and emerging therapies, are available.

Conclusions:

  • Effective management of phenylketonuria relies on early diagnosis and consistent treatment.
  • Ongoing research is exploring new avenues for pharmacological and non-pharmacological interventions to improve patient outcomes.
  • Comprehensive care addressing both physical and neurodevelopmental aspects is crucial for individuals with PKU.

More Related Videos

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures10:38

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

Published on: May 9, 2020

3.9K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.9K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
651
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
78
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
362
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391